Abstract
Meena Agarwal is a consultant in Adolescent and Child Psychiatry based at the Longlands Child Development Centre, Lancaster. Her interests in the dynamics of the family have resulted in her undertaking an MSc in Family Therapy. This contribution to the Journal describes her experience of introducing a new formulation of a drug used for Attention Deficit Hyperactivity Disorder (ADHD).
References
I. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade; Eur Child Adolesc Psychiatry 2004;13 Suppl l :17-30. Available from: https://doi.org/10.1007/s00787-004-1002-x
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorder . 4th Ed. Washington DC: American Psychiatric Association (APA);1994
World Health Organisation , International Classification of Diseases, 10th Ed. 1992
La k B, Taylor S, Nunn K. The disruptive disorders, chapter 5. IN Practical child psychiatry, the clinician's guide. BMJ Books;2003 pp.39-53
Taylor E. Syndromes of attention deficit and overactivity, chapter 17 , Physical treatment , chapter 51. IN Rutter M, Taylor E, Hersor L, (eds). Child and adolescent psychiatry. 3rd Ed. Oxford: Blackwell Scientific Publication; 1994 pp.285-307, p887
A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073-86. Available from: https://doi.org/10.1001/archpsyc.56.12.1073
Greenhill LL, Pliszb S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescent, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S. Available from: https://doi.org/10.1097/00004583-200202001-00003
Swan on J, Greenhill L, Pelham W, et al. Initiating Concerta (OROS Methylphenidate HCl) qd in children with attention-deficit hyperactivity disorder. J Clin Res 2000;3:59-76
Conners CK. Conners' teacher and parent rating scales - Revised (L). North Tonawanda: Multi-Health SystemsInc; 1997
British National Formulary. British Medical Association, Royal Pharmaceutical Society of Great Britain: BNF 47;March 2004
Steele M, Ricardelli R, Binder C. Poster presented at the CINP Congress. Paris: June 20-24;2004
Goldman LS, Genel M, Bezman RJ, Slanetz PJ . Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescent . Council on Scientific Affairs, American Medical Association. JAMA 1998;279(14): 1100-7. Available from: https://doi.org/10.1001/jama.279.14.1100
Wolraich ML, Greenhill LL, Pelham W, et al. Randomised controlled trial of oros methylphenidate once-a-day in children for attention deficit/hyperactivity disorder. Paediatrics 2001;108(4):883-92. Available from: https://doi.org/10.1542/peds.108.4.883